These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 37535237)

  • 1. The anti-inflammatory and immunological properties of SGLT-2 inhibitors.
    Bendotti G; Montefusco L; Pastore I; Lazzaroni E; Lunati ME; Fiorina P
    J Endocrinol Invest; 2023 Dec; 46(12):2445-2452. PubMed ID: 37535237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin.
    La Grotta R; de Candia P; Olivieri F; Matacchione G; Giuliani A; Rippo MR; Tagliabue E; Mancino M; Rispoli F; Ferroni S; Berra CC; Ceriello A; Prattichizzo F
    Cell Mol Life Sci; 2022 May; 79(5):273. PubMed ID: 35503137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure.
    Kasperova BJ; Mraz M; Svoboda P; Hlavacek D; Kratochvilova H; Modos I; Vrzackova N; Ivak P; Janovska P; Kobets T; Mahrik J; Riecan M; Steiner Mrazova L; Stranecky V; Netuka I; Cajka T; Kuda O; Melenovsky V; Stemberkova Hubackova S; Haluzik M
    Cardiovasc Diabetol; 2024 Jun; 23(1):223. PubMed ID: 38943140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
    Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
    J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors.
    Cersosimo E; Miles JM
    Curr Diabetes Rev; 2019; 15(4):314-327. PubMed ID: 30101716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database.
    de Germay S; Pambrun E; Pariente A; Grenet G; Bezin J; Faillie JL
    Diabetes Obes Metab; 2024 May; 26(5):1678-1686. PubMed ID: 38288619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents.
    Avranas K; Imprialos K; Stavropoulos K; Lales G; Manafis A; Skalkou A; Kihm L
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):94-103. PubMed ID: 29412124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression.
    Permana H; Audi Yanto T; Ivan Hariyanto T
    Diabetes Res Clin Pract; 2023 Jan; 195():110205. PubMed ID: 36502891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription Trends for the Antidiabetic Agents Used to Treat Type 2 Diabetes Mellitus in Japan from 2012-2020: a Time-Series Analysis.
    Iketani R; Imai S
    Biol Pharm Bull; 2023; 46(4):592-598. PubMed ID: 37005303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
    Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
    Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sodium-glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta-analysis.
    Duo Y; Gao J; Yuan T; Zhao W
    J Diabetes; 2023 Jan; 15(1):58-70. PubMed ID: 36610036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN-HF study.
    Correale M; Antohi EL; Inciardi RM; Mazzeo P; Coiro S; Ishihara S; Petroni R; Monitillo F; Leone M; Triggiani M; Sarwar CMS; Dungen HD; Talha KM; Brunetti ND; Butler J; Nodari S;
    ESC Heart Fail; 2023 Jun; 10(3):2066-2073. PubMed ID: 36924023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
    Paul SK; Bhatt DL; Montvida O
    Eur Heart J; 2021 May; 42(18):1728-1738. PubMed ID: 33289789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study.
    Chen J; Chang J; Shi Q; Li X; Wang L; Zhao H
    BMC Cardiovasc Disord; 2023 Oct; 23(1):495. PubMed ID: 37805494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108536. PubMed ID: 33181201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
    Rajasekeran H; Cherney DZ; Lovshin JA
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):358-367. PubMed ID: 28582367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice.
    Giaccari A; Pontremoli R; Perrone Filardi P
    Int J Cardiol; 2022 Mar; 351():66-70. PubMed ID: 34979145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.